-+ 0.00%
-+ 0.00%
-+ 0.00%

Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration

Benzinga·10/07/2026 05:38:01
  • First patient enrolled in cohort combining bexobrutideg with venetoclax
  • Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL
  • Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies